Padam Dugar, along with Persons Acting in Concert (PAC), has acquired a 15.01% stake in Colinz Laboratories Limited through an off-market transaction executed on May 21, 2026. The acquisition, disclosed to BSE Limited under Regulation 29(1) and 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, involved the purchase of 3,78,000 equity shares. The acquirers do not belong to the promoter or promoter group of the target company. The company received the requisite disclosures on May 22, 2026, and May 25, 2026, confirming the transaction details.

Details of the Acquisition

The acquisition was structured as an off-market purchase, involving direct transfers between parties. The total equity share capital of Colinz Laboratories remains unchanged at Rs. 2,51,91,000, divided into 25,19,100 fully paid-up equity shares of Rs. 10 each. The acquirers included Padam Dugar, Annjana Dugar, Likhitta Dugar, and Antariksh Dugar. Prior to this transaction, the holding of all acquirers was nil.

Shareholding Breakdown

The following table details the shares acquired by each individual and their resulting post-transaction holdings:

The disclosures were signed by the acquirers on May 25, 2026. Ganesh Chitte, the CFO of Colinz Laboratories, submitted the intimation to the exchange.

Colinz Laboratories Limited has completed its regulatory compliance process by submitting newspaper clippings of its FY26 audited financial results to the Bombay Stock Exchange. The pharmaceutical company published its results in Free Press Journal and Navshakti newspapers on April 30, 2026, fulfilling requirements under Regulation 47(3) of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Regulatory Compliance and Publication

Additional Director Vijaya Mani (DIN: 11363910) submitted the newspaper clippings to BSE's Corporate Relations Department on April 30, 2026. The submission covered audited financial results for the quarter and year ended March 31, 2026, which were previously approved by the Board of Directors on April 29, 2026.

Financial Performance Highlights

The published results demonstrate strong quarterly performance with revenue reaching ₹192.24 lakhs in Q4 FY26, compared to ₹152.70 lakhs in Q4 FY25. Net profit for the quarter stood at ₹17.12 lakhs versus ₹15.04 lakhs in the corresponding previous quarter.

Annual Financial Overview

For the full financial year FY26, the company reported total revenue of ₹662.05 lakhs compared to ₹682.56 lakhs in FY25. Annual net profit increased to ₹51.45 lakhs from ₹49.66 lakhs in the previous year. Total comprehensive income for FY26 reached ₹56.87 lakhs against ₹52.55 lakhs in FY25.

Audit and Board Approval

The financial results received an unqualified audit opinion from statutory auditors and were reviewed by the Audit Committee before Board approval. The equity share capital remained stable at ₹251.91 lakhs with a face value of ₹10 per share. The company operates from its corporate office at A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, Mumbai - 400 078.

Publication and Disclosure Framework

The newspaper publications fulfill SEBI's mandatory disclosure requirements, ensuring transparency for stakeholders. Complete financial results are available on BSE's website at www.bseindia.com and the company's website. The published extracts include key financial metrics, earnings per share data, and comprehensive income statements for both quarterly and annual periods.